Foamix Pharmaceuticals Ltd. Share Price Nasdaq
Equities
IL0011334385
Biotechnology & Medical Research
Sales 2024 * | 400K 30.9M | Sales 2025 * | 250K 19.31M | Capitalization | 32.69M 2.52B |
---|---|---|---|---|---|
Net income 2024 * | -32M -2.47B | Net income 2025 * | -40M -3.09B | EV / Sales 2024 * | 81.7 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 131 x |
P/E ratio 2024 * |
-2.78
x | P/E ratio 2025 * |
-2.85
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.55% |
Latest transcript on Foamix Pharmaceuticals Ltd.
Managers | Title | Age | Since |
---|---|---|---|
David Domzalski
CEO | Chief Executive Officer | 58 | 29/02/20 |
Tyler Zeronda
DFI | Director of Finance/CFO | 38 | - |
Iain Stuart
CTO | Chief Tech/Sci/R&D Officer | 51 | 29/02/20 |
Members of the board | Title | Age | Since |
---|---|---|---|
Pat LePore
BRD | Director/Board Member | 69 | 09/09/20 |
Steven Basta
BRD | Director/Board Member | 59 | 31/12/14 |
Anthony Bruno
BRD | Director/Board Member | 68 | 29/02/20 |
1st Jan change | Capi. | |
---|---|---|
+22.00% | 127B | |
+24.77% | 117B | |
+26.84% | 27.67B | |
-18.49% | 20.33B | |
-15.24% | 16.79B | |
-17.79% | 15.63B | |
+13.42% | 14.84B | |
-47.10% | 14.65B | |
+57.91% | 14.43B |